Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)
- 1 September 2002
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 90 (6) , 585-590
- https://doi.org/10.1016/s0002-9149(02)02560-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2001
- Platelet Glycoprotein IIb/IIIa Integrin Blockade With Eptifibatide in Coronary Stent InterventionJAMA, 2001
- Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trialThe Lancet, 2000
- Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes MellitusCirculation, 1999
- Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa ReceptorsNew England Journal of Medicine, 1999
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Increased Restenosis in Diabetes Mellitus After Coronary Interventions Is Due to Exaggerated Intimal HyperplasiaCirculation, 1997
- Potential mechanisms promoting restenosis in diabetic patientsJournal of the American College of Cardiology, 1996
- Hyperaggregation of Platelets Detected by Whole Blood Platelet Aggregometry in Newly Diagnosed Noninsulin-dependent Diabetes MellitusAmerican Journal of Clinical Pathology, 1993
- Evidence for abnormal platelet glycoprotein expression in diabetes mellitusEuropean Journal of Clinical Investigation, 1990